Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / ORPATHYS Approved for Gastric Cancer in China
Regulatory drug approval

ORPATHYS Approved for Gastric Cancer in China

Analysis based on 6 articles · First reported Jul 02, 2026 · Last updated Jul 02, 2026

Sentiment
80
Attention
6
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The approval of ORPATHYS (savolitinib) in China is expected to positively impact the stock prices of HUTCHMED and AstraZeneca due to expanded market access and potential revenue growth from a new indication in a significant market. This development also highlights the increasing importance of precision medicine in oncology, potentially driving further investment and innovation in the pharmaceutical and biotechnology sectors.

pharmaceuticals biotechnology
Event Summary

HUTCHMED announced that its New Drug Application for ORPATHYS (savolitinib) has received conditional approval from the China — National Medical Products Administration for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China. This approval is based on positive data from a pivotal Phase II study, which demonstrated a 32.3% objective response rate. ORPATHYS (savolitinib) is jointly developed by HUTCHMED and AstraZeneca and is the first selective MET inhibitor approved in China for this indication. This marks the third approved indication for ORPATHYS (savolitinib) in China and is expected to address a significant unmet medical need for gastric cancer patients in the country.

Key Actions
100 China — National Medical Products Administration granted conditional approval HUTCHMED
95 HUTCHMED announced approval
70 AstraZeneca commercializes
Entities Involved
stock
HUTCHMED
HUTCHMED, a biopharmaceutical company, received conditional approval from the China — National Medical Products Administration for its drug ORPATHYS (savolitinib) for gastric cancer treatment in China. This marks the third approved indication for ORPATHYS in China and validates HUTCHMED's R&D platform.
Importance 100.0 Sentiment 85.0
oth
ORPATHYS
ORPATHYS (savolitinib), a selective MET inhibitor, received conditional approval in China for treating MET-amplified advanced gastric cancer, expanding its market and therapeutic application.
Importance 95.0 Sentiment 80.0
govactor
China — National Medical Products Administration
The China — National Medical Products Administration granted conditional approval for ORPATHYS (savolitinib) for the treatment of gastric cancer, enabling its commercialization in China.
Importance 90.0 Sentiment 0.0
stock
AstraZeneca
AstraZeneca, as HUTCHMED's partner, jointly developed and commercializes ORPATHYS (savolitinib). The approval in China for gastric cancer expands its market reach and reinforces its precision medicine strategy.
Importance 80.0 Sentiment 70.0
cnt
China
The approval of ORPATHYS (savolitinib) in China addresses a significant unmet medical need for gastric cancer patients in the country, where gastric cancer is a leading cause of cancer death.
Importance 70.0 Sentiment 0.0
per
Lin Shen
Professor Lin Shen, a leading Principal Investigator, highlighted the significance of ORPATHYS (savolitinib) approval for biomarker-driven precision medicine in gastrointestinal oncology.
Importance 40.0 Sentiment 0.0
per
Johnny Cheng
Johnny Cheng, Acting CEO and CFO of HUTCHMED, emphasized the importance of ORPATHYS (savolitinib) approval as a testament to HUTCHMED's commitment to innovation and addressing unmet medical needs.
Importance 40.0 Sentiment 0.0
per
Mary Guan
Mary Guan, General Manager of AstraZeneca China Oncology Business, underscored the approval of ORPATHYS (savolitinib) as a pivotal chapter in the joint development journey with HUTCHMED, reinforcing their shared vision for precision medicine.
Importance 40.0 Sentiment 0.0
Relationships
China — National Medical Products Administration related ↔ China
AstraZeneca related ↔ China
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.